Not Signed In -
Bevacizumab Injection |
Avastin; bevacizumab |
Image:Bevacizumab.png Bevacizumab Systematic (IUPAC) name (not applicable) Identifiers CAS number 216974-75-3 ATC code L01XC07 PubChem (none) DrugBank BTD00087 Chemical data Formula ? Mol. weight 149,000 Pharmacokinetic data Bioavailability 100% (IV only) Metabolism ? Half life 20 days (range: 11-50 days) Excretion ? Therapeutic considerations Pregnancy cat. C (USA) Legal status ℞ Prescription only Routes IV Bevacizumab (A ...
Wikipedia - [full article]
Bevacizumab Injection Clinical Trials
- Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
ClinicalTrials.gov Identifier: NCT00548197 - Recruiting
Intravitreal Bevacizumab Injection; Pars Plana Vitrectomy; Tractional Retinal Detachment; Diabetic Retinopathy
- Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
ClinicalTrials.gov Identifier: NCT00370370 - Active, not recruiting
Neovascular Age-Related Macular Degeneration
- Prevention of Vision Loss in Patients With AMD by Intravitreal Injection of Bevacizumab and Ranibizumab
ClinicalTrials.gov Identifier: NCT00559715 - Not yet recruiting
Age-Related Neovascular Macular Degeneration
- Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
ClinicalTrials.gov Identifier: NCT00436709 - Active, not recruiting
Breast Cancer
- Bevacizumab as an Adjuvant for Resectable Ductal Adenocarcinoma of the Pancreas
ClinicalTrials.gov Identifier: NCT00158392 - Recruiting
- TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
ClinicalTrials.gov Identifier: NCT00057720 - Active, not recruiting
Ovarian Neoplasms
- Bevacizumab and Irinotecan in Treating Patients With Recurrent High-Grade Malignant Glioma That Progressed on Bevacizumab Alone
ClinicalTrials.gov Identifier: NCT00393094 - Recruiting
Brain and Central Nervous System Tumors
- Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial
ClinicalTrials.gov Identifier: NCT00370422 - Active, not recruiting
Diabetic Macular Edema
- Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabin/Cisplatin Plus Bevacizumab
ClinicalTrials.gov Identifier: NCT00536640 - Recruiting
Carcinoma, Non-Small-Cell Lung
- Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
ClinicalTrials.gov Identifier: NCT00137826 - Active, not recruiting
Mesothelioma
- Neoadjuvant Chemoradiation with Bevacizumab for Rectal Cancer
ClinicalTrials.gov Identifier: NCT00113230 - Active, not recruiting
Rectal Cancer
- Combination of Capecitabine (Xeloda) and Bevacizumab (Avastin) for Treatment of Metastatic Breast Cancer in Patients Who Are HER2 Negative (Do Not Have Too Many Copies of the HER2 Gene) Followed by Chemotherapy Combined with Bevacizumab If Disease Progres
ClinicalTrials.gov Identifier: NCT00121836 - Active, not recruiting
Breast Cancer
- Primary Effusion Lymphoma: A Pilot Trial Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy with Bortezomib, Zidovudine and Valganciclovir
ClinicalTrials.gov Identifier: NCT00121576 - Recruiting
- A 2x2 (4-way) study of capecitabine in combo w/ oxaliplatin (XELOX) w/ or w/out bevacizumab vs. fluorouracil/leucovorin w/ oxaliplatin (FOLFOX-4) w/ or w/out bevacizumab as first-line treatment for pts w/ metastatic colorectal cancer
ClinicalTrials.gov Identifier: NCT00069095 - Active, not recruiting
Metastatic Colorectal Cancer
- Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
ClinicalTrials.gov Identifier: NCT00114179 - Active, not recruiting
adenocarcinoma of the pancreas; stage III pancreatic cancer; stage II pancreatic cancer
- Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer
ClinicalTrials.gov Identifier: NCT00307723 - Recruiting
Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma
- Phase I Study of Bevacizumab to Treat Solid Tumors in Children
ClinicalTrials.gov Identifier: NCT00080561 - Recruiting
Neoplasms
- A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
ClinicalTrials.gov Identifier: NCT00370552 - Recruiting
Metastatic Breast Cancer
- Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00425646 - Recruiting
Lung Cancer
- Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
ClinicalTrials.gov Identifier: NCT00511992 - Recruiting
Advanced Ovarian Carcinoma; Primary Peritoneal Carcinoma; Ovarian Carcinosarcoma
- Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
ClinicalTrials.gov Identifier: NCT00268450 - Recruiting
Bladder Cancer
- Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD
ClinicalTrials.gov Identifier: NCT00370539 - Recruiting
Neovascular Age-Related Macular Degeneration
- Gemcitabine, Oxaliplatin in Combination with Bevacizumab in Patients with Hepatocellular Carcinoma
ClinicalTrials.gov Identifier: NCT00142467 - Active, not recruiting
Hepatocellular Carcinoma
- Study of Pemetrexed and Bevacizumab in Patients with Head and Neck Cancer
ClinicalTrials.gov Identifier: NCT00222729 - Recruiting
Cancer
- 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage I/II Rectal Cancer
ClinicalTrials.gov Identifier: NCT00308516 - Recruiting
Rectal Cancer; Cancer of the Rectum; Colorectal Cancer
- A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small-Cell Lung Cancer)
ClinicalTrials.gov Identifier: NCT00095225 - Active, not recruiting
Non-Small-Cell Lung Carcinoma; Neoplasm Recurrence, Local
- Bevacizumab in Combination with Temozolomide in Patients with Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00137774 - Active, not recruiting
Metastatic Neuroendocrine Tumor; Neuroendocrine Tumor
- Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
ClinicalTrials.gov Identifier: NCT00025337 - Active, not recruiting
stage III colon cancer; stage IV colon cancer; stage III rectal cancer; Stage IV rectal cancer; recurrent colon cancer; recurrent rectal cancer; ...
- Penile Injection Anxiety
ClinicalTrials.gov Identifier: NCT00582231 - Recruiting
Penile Injection Therapy; Erectile Dysfunction; Radical Pelvic Surgery
- Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
ClinicalTrials.gov Identifier: NCT00536939 - Recruiting
Breast Cancer
- BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
ClinicalTrials.gov Identifier: NCT00095459 - Recruiting
Neoplasms
- Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
ClinicalTrials.gov Identifier: NCT00055913 - Active, not recruiting
Head and Neck Cancer
- Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
ClinicalTrials.gov Identifier: NCT00025233 - Active, not recruiting
recurrent cervical cancer; cervical squamous cell carcinoma
- Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
ClinicalTrials.gov Identifier: NCT00139360 - Recruiting
Metastatic Melanoma
- Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
ClinicalTrials.gov Identifier: NCT00255762 - Active, not recruiting
Recurrent Melanoma; Stage IV Melanoma
- Bevacizumab Erlotinib Study in Advanced Ovarian Cancer
ClinicalTrials.gov Identifier: NCT00130520 - Recruiting
Ovarian Neoplasms
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00012272 - Active, not recruiting
Stage IV rectal cancer; stage IV colon cancer
- Safety of KAI-9803 for Injection with Angioplasty following Heart Attack
ClinicalTrials.gov Identifier: NCT00093197 - Active, not recruiting
Myocardial Infarction
- Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00083031 - Active, not recruiting
recurrent breast cancer; stage IV breast cancer
- XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
ClinicalTrials.gov Identifier: NCT00557713 - Recruiting
Rectal Neoplasms; Locally Advanced Rectal Adenocarcinoma
- Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
ClinicalTrials.gov Identifier: NCT00016107 - Active, not recruiting
stage IV prostate cancer; adenocarcinoma of the prostate; recurrent prostate cancer
- Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
ClinicalTrials.gov Identifier: NCT00023959 - Active, not recruiting
Head and Neck Cancer
- A Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in Patients With Stage 5 Chronic Kidney Disease
ClinicalTrials.gov Identifier: NCT00257920 - Recruiting
Stage 5 Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism
- Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients with Advanced Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00159432 - Recruiting
Colorectal Cancer
- Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
ClinicalTrials.gov Identifier: NCT00533429 - Recruiting
Non-Small Cell Lung Cancer
- Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00028990 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
- Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00079040 - Active, not recruiting
extensive stage small cell lung cancer
- Bevacizumab with Or Without Cyclophosphamide and Methotrexate: a Pilot Study in Women with Operable Breast Cancer
ClinicalTrials.gov Identifier: NCT00121134 - Recruiting
Breast Cancer
- A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00257608 - Recruiting
Non-Small-Cell Lung Carcinoma
- Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00088998 - Active, not recruiting
Male Breast Cancer; recurrent breast cancer; stage IV breast cancer
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
ClinicalTrials.gov Identifier: NCT00112918 - Active, not recruiting
stage II colon cancer; stage III colon cancer
- A Study to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva for Advanced Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov Identifier: NCT00130728 - Recruiting
Carcinoma, Non-Small-Cell Lung
- Trial of Cetuximab, Bevacizumab and 5FU/Leucovorin Versus Oxaliplatin, Bevacizumab and 5FU/Leucovorin in Metastatic Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00252564 - Recruiting
Metastatic Colorectal Cancer
- Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
ClinicalTrials.gov Identifier: NCT00126490 - Active, not recruiting
Stage IV Renal Cell Cancer; recurrent renal cell cancer
- Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
ClinicalTrials.gov Identifier: NCT00126633 - Active, not recruiting
stage IVA pancreatic cancer; stage IVB pancreatic cancer; adenocarcinoma of the pancreas
- Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
ClinicalTrials.gov Identifier: NCT00193258 - Active, not recruiting
Prostate Cancer
- Bevacizumab(Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review
ClinicalTrials.gov Identifier: NCT00322725 - Active, not recruiting
Cancer
- Erlotinib and Bevacizumab in Treating Women With Stage IV Breast Cancer
ClinicalTrials.gov Identifier: NCT00054132 - Active, not recruiting
stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
- Cytokine Working Group Phase II Study of Bevacizumab & IL-2 in Metastatic Renal Cancer Patients
ClinicalTrials.gov Identifier: NCT00142142 - Recruiting
Metastatic renal cell carcinoma
- Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
ClinicalTrials.gov Identifier: NCT00066677 - Active, not recruiting
adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
- Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
ClinicalTrials.gov Identifier: NCT00323739 - Active, not recruiting
Kidney Cancer
- Multimodality Treatment for Patients with Resectable NSCLC-BEACON Study: Bevacizumab+Chemotherapy for Operable NSCLC
ClinicalTrials.gov Identifier: NCT00130780 - Recruiting
Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell
- Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
ClinicalTrials.gov Identifier: NCT00022659 - Active, not recruiting
stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; peritoneal cavity cancer
- Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
ClinicalTrials.gov Identifier: NCT00268359 - Active, not recruiting
Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor; ...
- Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
ClinicalTrials.gov Identifier: NCT00100815 - Active, not recruiting
adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer; recurrent pancreatic cancer
- MRI in Patients Receiving Bevacizumab and Irinotecan for Recurrent Malignant Glioma
ClinicalTrials.gov Identifier: NCT00352521 - Active, not recruiting
Brain and Central Nervous System Tumors
- Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
ClinicalTrials.gov Identifier: NCT00084604 - Active, not recruiting
stage III gastric cancer; stage IV gastric cancer; recurrent gastric cancer; adenocarcinoma of the stomach
- Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
ClinicalTrials.gov Identifier: NCT00035867 - Active, not recruiting
Myelodysplastic Syndromes
- Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
ClinicalTrials.gov Identifier: NCT00096278 - Active, not recruiting
adenocarcinoma of the colon; stage II colon cancer; stage III colon cancer
- Treatment of HER2-Positive Metastatic Breast Cancer with Herceptin and Bevacizumab (antibodies against HER2 and VEGF)
ClinicalTrials.gov Identifier: NCT00095706 - Recruiting
Breast Cancer
- Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
ClinicalTrials.gov Identifier: NCT00055692 - Active, not recruiting
adult primary hepatocellular carcinoma; recurrent adult primary liver cancer; localized unresectable adult primary liver cancer
- Cisplatin, Irinotecan, and Bevacizumab in Treating Patients with Extensive-Stage Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00118235 - Active, not recruiting
extensive stage small cell lung cancer; Recurrent Small Cell Lung Cancer
- Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
ClinicalTrials.gov Identifier: NCT00313768 - Active, not recruiting
Carcinoma, Non-Small-Cell Lung
- Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
ClinicalTrials.gov Identifier: NCT00112528 - Active, not recruiting
duct cell adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer; recurrent pancreatic cancer
- Bevacizumab and Combination Chemotherapy in Treating Patients Who Have Undergone Surgery for Breast Cancer That Has Spread to the Lymph Nodes
ClinicalTrials.gov Identifier: NCT00119262 - Active, not recruiting
stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; Male Breast Cancer
- Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer.
ClinicalTrials.gov Identifier: NCT00177307 - Active, not recruiting
Cancer
- Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
ClinicalTrials.gov Identifier: NCT00344617 - Active, not recruiting
Choroidal Neovascularisation; Polypoidal Choroidal Vasculopathy
- A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
ClinicalTrials.gov Identifier: NCT00345163 - Active, not recruiting
Glioblastoma
- Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ClinicalTrials.gov Identifier: NCT00088894 - Active, not recruiting
adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ...
- Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00016094 - Active, not recruiting
recurrent adult diffuse large cell lymphoma; recurrent adult Burkitt's lymphoma; recurrent mantle cell lymphoma; anaplastic large cell lymphoma
- A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
ClinicalTrials.gov Identifier: NCT00336323 - Active, not recruiting
Diabetic Retinopathy
- Bevacizumab in Treating Patients With Advanced Solid Tumors
ClinicalTrials.gov Identifier: NCT00416637 - Active, not recruiting
Unspecified Adult Solid Tumor, Protocol Specific
- A Trial of Taxol and Bevacizumab vs. Gemcitabine, Taxol, and Bevacizumab in Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00320541 - Recruiting
Breast Cancer; Cancer of Breast; Cancer of the Breast; Breast Neoplasms
- Interferon alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
ClinicalTrials.gov Identifier: NCT00072046 - Active, not recruiting
Stage IV Renal Cell Cancer; renal clear cell carcinoma; recurrent renal cell cancer
- First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
ClinicalTrials.gov Identifier: NCT00537901 - Active, not recruiting
Colonic Neoplasms; Rectal Neoplasms
- Combination Chemotherapy, Bevacizumab, and Cetuximab in Treating Patients With Stage IV Colorectal Cancer That Cannot Be Removed by Surgery
ClinicalTrials.gov Identifier: NCT00100841 - Active, not recruiting
adenocarcinoma of the colon; adenocarcinoma of the rectum; stage IV colon cancer; Stage IV rectal cancer; recurrent colon cancer; ...
- ABT-510 and Bevacizumab in Treating Patients With Advanced Solid Tumors
ClinicalTrials.gov Identifier: NCT00276562 - Active, not recruiting
Unspecified Adult Solid Tumor, Protocol Specific
- Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
ClinicalTrials.gov Identifier: NCT00276575 - Active, not recruiting
Unspecified Adult Solid Tumor, Protocol Specific
- Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
ClinicalTrials.gov Identifier: NCT00314353 - Active, not recruiting
Colorectal Neoplasms
- Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
ClinicalTrials.gov Identifier: NCT00150657 - Recruiting
Non-small cell lung cancer
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00021060 - Active, not recruiting
recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
- Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
ClinicalTrials.gov Identifier: NCT00055237 - Recruiting
Kaposi's Sarcoma; HIV Infections; HIV Seronegativity
- Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00062426 - Active, not recruiting
adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent colon cancer; stage IV colon cancer; recurrent rectal cancer; ...
- Docetaxel With or Without Bevacizumab Followed by Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Locally Advanced Breast Cancer
ClinicalTrials.gov Identifier: NCT00027885 - Active, not recruiting
stage IV breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; Male Breast Cancer
- Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
ClinicalTrials.gov Identifier: NCT00126542 - Active, not recruiting
recurrent ovarian epithelial cancer; stage IV ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer
- Adverse Drug Reactions of Different Brands of Ceftazidime Injection
ClinicalTrials.gov Identifier: NCT00173901 - Active, not recruiting
Infection
- Topical Amethocaine Gel for Intramuscular Injection in Term Neonates
ClinicalTrials.gov Identifier: NCT00267111 - Active, not recruiting
Pain
- Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
ClinicalTrials.gov Identifier: NCT00015951 - Active, not recruiting
recurrent adult acute myeloid leukemia; relapsing chronic myelogenous leukemia; blastic phase chronic myelogenous leukemia; ...
- Validation of Self-Reported Needle Sharing Among Injection Drug Users
ClinicalTrials.gov Identifier: NCT00341081 - Active, not recruiting
Viral Infection
- Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00193375 - Active, not recruiting
Lung Cancer
Resources
- Avastin (Drug Digest)
- Avastin Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
